Cargando…
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) in adults remains a challenging disease to treat, and novel therapies are needed. Precursor-B ALL comprises 80% of cases, and the CD19 antigen is expressed in nearly all precursor-B ALL patients. Bispecific T-cell-engaging antibodies are novel bioengineered protein...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650887/ https://www.ncbi.nlm.nih.gov/pubmed/23671399 http://dx.doi.org/10.2147/CPAA.S42689 |
_version_ | 1782269127220527104 |
---|---|
author | Portell, Craig A Wenzell, Candice M Advani, Anjali S |
author_facet | Portell, Craig A Wenzell, Candice M Advani, Anjali S |
author_sort | Portell, Craig A |
collection | PubMed |
description | Acute lymphoblastic leukemia (ALL) in adults remains a challenging disease to treat, and novel therapies are needed. Precursor-B ALL comprises 80% of cases, and the CD19 antigen is expressed in nearly all precursor-B ALL patients. Bispecific T-cell-engaging antibodies are novel bioengineered proteins. The bispecific T-cell-engaging antibody blinatumomab engages polyclonal T cells to CD19-expressing B cells. By binding to both CD3 and CD19, blinatumomab physically brings these T cells in close proximity to malignant B cells and potentiates T-cell-induced cytotoxic cell kill. Blinatumomab requires continuous intravenous infusion due to its short half-life, the need for continuous exposure for the drug to exert sufficient efficacy, and lessened toxicity. A phase II trial of B-cell ALL patients with persistent or relapsed minimal residual disease demonstrated an 80% rate of complete molecular remission. Cytokine-release syndrome and central nervous system events, such as seizures and encephalopathy, are reversible toxicities. Promising results in B-cell ALL with minimal residual disease have led to further evaluation of this drug in newly diagnosed and relapsed B-cell ALL. |
format | Online Article Text |
id | pubmed-3650887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-36508872013-05-13 Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia Portell, Craig A Wenzell, Candice M Advani, Anjali S Clin Pharmacol Review Acute lymphoblastic leukemia (ALL) in adults remains a challenging disease to treat, and novel therapies are needed. Precursor-B ALL comprises 80% of cases, and the CD19 antigen is expressed in nearly all precursor-B ALL patients. Bispecific T-cell-engaging antibodies are novel bioengineered proteins. The bispecific T-cell-engaging antibody blinatumomab engages polyclonal T cells to CD19-expressing B cells. By binding to both CD3 and CD19, blinatumomab physically brings these T cells in close proximity to malignant B cells and potentiates T-cell-induced cytotoxic cell kill. Blinatumomab requires continuous intravenous infusion due to its short half-life, the need for continuous exposure for the drug to exert sufficient efficacy, and lessened toxicity. A phase II trial of B-cell ALL patients with persistent or relapsed minimal residual disease demonstrated an 80% rate of complete molecular remission. Cytokine-release syndrome and central nervous system events, such as seizures and encephalopathy, are reversible toxicities. Promising results in B-cell ALL with minimal residual disease have led to further evaluation of this drug in newly diagnosed and relapsed B-cell ALL. Dove Medical Press 2013-04-12 /pmc/articles/PMC3650887/ /pubmed/23671399 http://dx.doi.org/10.2147/CPAA.S42689 Text en © 2013 Portell et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Portell, Craig A Wenzell, Candice M Advani, Anjali S Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia |
title | Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia |
title_full | Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia |
title_fullStr | Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia |
title_full_unstemmed | Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia |
title_short | Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia |
title_sort | clinical and pharmacologic aspects of blinatumomab in the treatment of b-cell acute lymphoblastic leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650887/ https://www.ncbi.nlm.nih.gov/pubmed/23671399 http://dx.doi.org/10.2147/CPAA.S42689 |
work_keys_str_mv | AT portellcraiga clinicalandpharmacologicaspectsofblinatumomabinthetreatmentofbcellacutelymphoblasticleukemia AT wenzellcandicem clinicalandpharmacologicaspectsofblinatumomabinthetreatmentofbcellacutelymphoblasticleukemia AT advanianjalis clinicalandpharmacologicaspectsofblinatumomabinthetreatmentofbcellacutelymphoblasticleukemia |